Population pharmacokinetics of subcutaneous infliximab CT-P13 in Crohn's disease and ulcerative colitis.

Jurij HanželLaura H BukkemsKrisztina B GecseGeert R D'HaensRon A A Mathôt

Published in: Alimentary pharmacology & therapeutics (2021)

This first population PK model for subcutaneous CT-P13 supports fixed subcutaneous maintenance dosing, although heavy patients had lower cumulative drug exposure.

Keyphrases

ulcerative colitis
end stage renal disease
computed tomography
image quality
ejection fraction
newly diagnosed
dual energy
contrast enhanced
peritoneal dialysis
prognostic factors
magnetic resonance
drug induced
patient reported